LivaNova Annual Short Term Incentive Plan and CEO’s compensation


LivaNova Annual Short Term Incentive Plan and CEO’s compensation

London, February 28, 2017 – LivaNova PLC (NASDAQ:LIVN; LSE: LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced that, on 28 February 2017, LivaNova filed with the U.S. Securities and Exchange Commission its Current Report on Form 8-K, a copy of which can be found at

A copy of the Form 8-K is being submitted to the UK Listing Authority via the National Storage Mechanism and will shortly be available for inspection at

About LivaNova

LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. LivaNova’s advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems. Headquartered in London and with a presence in more than 100 countries worldwide, the company employs approximately 4,600 employees.

LivaNova operates as three business franchises: Cardiac Surgery, Neuromodulation and Cardiac Rhythm Management, with operating headquarters in Mirandola (Italy), Houston (U.S.A.) and Clamart (France), respectively.

For more information, please visit, or contact:

Catherine Moroz

Director, Company Secretariat

Phone: +44 (0) 203 325 0662


Karen King

Vice President, Investor Relations & Corporate Communications

Phone: +1 (281) 228-7262


Short Name: LivaNova PLC
Category Code: MSCH
Sequence Number: 578560
Time of Receipt (offset from UTC): 20170228T133456+0000


LivaNova PLC


LivaNova PLC